Although a number of studies have evaluated the contribution of IL-17 in the development of MS, its concentrations have not been assessed adequately in MS patients with respect to gender, medication, forms of MS and IL-23R gene polymorphisms,. This evidence concerns the gene IL17A and myeloid sarcoma.